Long Ideas - Merge Healthcare (NASDAQ:MRGE) reported adjusted 3Q 2012 revenues and EPS of $61.0 million and $0.01, compared to Wall St. Consensus expectations of $62.9 million and … Continue Reading
Read nowLong Ideas - Navidea Biopharmaceuticals (NASDAQ:NAVB) announced that on October 30th it resubmitted its new drug application (NDA) for Lymphoseek in response to the FDA’s Complete Response Letter … Continue Reading
Read nowLong Ideas - Acorda Therapeutics (NASDAQ:ACOR) reported 3Q 2012 revenues and EPS of $77.4 million and $0.24, vs. the Consensus estimates of $75.1 million and $0.10, respectively. Sales … Continue Reading
Read nowLong Ideas - Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been under pressure as investors await the supply of generic leucovorin to increase and compete with SPPI’s branded cancer … Continue Reading
Read nowMost Popular - Shares of St. Jude Medical (NYSE:STJ) fell Thursday after the company announced negative results from the RESPECT trial, which was expected to support U.S. approval … Continue Reading
Read nowLong Ideas - Merck & Co. (NYSE:MRK) reported better than expected earnings Friday morning, with EPS of $0.95 vs. the Street Consensus of $0.93. While 3Q total revenues … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … Continue Reading
Read now